Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 43(11): 5151-5, 1983 Nov.
Article in English | MEDLINE | ID: mdl-6616452

ABSTRACT

The in vivo antitumor activity of a crude extract from the bitter melon (Momordica charantia) was determined. The extract inhibited tumor formation in CBA/H mice which had been given i.p. injections of 1.0 X 10(5) CBA/Dl tumor cells (77% of the untreated mice with tumors versus 33% of the treated mice with tumors after 6 weeks). The extract also inhibited tumor formation in DBA/2 mice which had been given i.p. injections of either 1 X 10(5) P388 tumor cells (0% of untreated mice survived after 30 days versus 40% survival of the treated mice) or 1 X 10(5) L1210 tumor cells (0% survival of untreated mice versus 100% of treated mice after 30 days). The in vivo antitumor effect required both the prior exposure of tumor cells to the extract (2 hr) in vitro and i.p., biweekly injections of the extract into the mice. The optimum dose for tumor inhibition (8 micrograms protein, biweekly, i.p.) was not toxic to mice for at least 45 days of treatment. This same treatment caused a marked enhancement of C3H mouse thymic cell response to concanavalin A in vitro. When compared to the untreated control mice, the bitter melon-injected animals exhibited a 4-fold-higher incorporation of tritiated thymidine into trichloroacetic acid-precipitable material after 48 hr of exposure to 50 micrograms of concanavalin A. Nylon wool-purified spleen cells from these same bitter melon-treated mice exhibited an enhanced mixed lymphocyte reaction when exposed to irradiated P388 stimulator cells (186% of the untreated control mice). These data indicate that in vivo enhancement of immune functions may contribute to the antitumor effects of the bitter melon extract.


Subject(s)
Leukemia L1210/drug therapy , Leukemia P388/drug therapy , Leukemia, Experimental/drug therapy , Plant Extracts/therapeutic use , Plants, Medicinal , Animals , Drug Administration Schedule , Injections, Intraperitoneal , Mice , Mice, Inbred C3H , Mice, Inbred CBA , Mice, Inbred DBA , Plant Extracts/administration & dosage , Plant Extracts/toxicity
2.
Leuk Res ; 7(1): 97-100, 1983.
Article in English | MEDLINE | ID: mdl-6834884

ABSTRACT

The content of calmodulin, as measured by a radioimmunoassay, in homogenates of two human leukemic cell lines (IM9 and Molt-4) was about 10-fold higher than that of normal human peripheral lymphocytes. These elevated calmodulin levels existed regardless of the proliferation status of the cells. Normal human lymphocytes stimulated with concanavalin A (con A) did not exhibit these elevated calmodulin levels. Likewise, leukemic cells which were 'blocked' from dividing through the addition of thymidine did not exhibit lower or 'normal' cellular calmodulin levels. These increased levels of calmodulin could contribute to the altered calcium regulation which exists in human leukemic lymphocytes.


Subject(s)
Calcium-Binding Proteins/analysis , Calmodulin/analysis , Leukemia/metabolism , Cell Line , Concanavalin A/pharmacology , Humans , Lymphocyte Activation , Lymphocytes/drug effects , Lymphocytes/metabolism , Radioimmunoassay
3.
Prep Biochem ; 13(4): 371-93, 1983.
Article in English | MEDLINE | ID: mdl-6196772

ABSTRACT

We have previously reported that a crude aqueous extract of the bitter melon (Momordica charantia) has both cytostatic and cytotoxic activities, and is a competitive inhibitor of guanylate cyclase activity. This crude preparation kills human leukemic lymphocytes in a dose-dependent manner while not affecting the viability of normal human lymphocytes at these same doses. In this report we describe the purification and characterization of one of these cytostatic factors which also exhibits anti-viral activity. The partially purified factor was both cytostatic to BHK-21 cells and inhibitory to VSV plaque formation in a dose-dependent manner. This preparation was inhibitory to both viral and host cell RNA and protein synthesis as early as 30 min after addition to these samples. As determined by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), this purified factor is a single component with a molecular weight corresponding to 40,000 daltons. The factor is sensitive to boiling and to pre-treatments with trypsin, but not ribonuclease (RNAse), or deoxyribonuclease (DNAse). As determined by radioactive precursor uptake and incorporation studies, the purified factor inhibits both RNA and protein synthesis in intact tissue culture cells and inhibits protein synthesis in a cell-free wheat germ system. DNA synthesis was slightly stimulated. The purified factor is cytostatic for both BHK-21 and for the IM9 leukemic cell lines for at least 120 h. The cytostatic component had no effect on cellular cyclic GMP metabolism.


Subject(s)
Antiviral Agents/isolation & purification , Cytotoxins/isolation & purification , Plant Extracts/pharmacology , Animals , Cell Survival/drug effects , Cells, Cultured/drug effects , Cricetinae , DNA/biosynthesis , Humans , Lymphocytes/drug effects , Protein Biosynthesis , RNA/biosynthesis , Vesicular stomatitis Indiana virus/drug effects , Viral Plaque Assay
4.
Prep Biochem ; 13(5): 397-421, 1983.
Article in English | MEDLINE | ID: mdl-6142453

ABSTRACT

We have previously reported that a crude aqueous extract of the bitter melon (Momordica charantia) has both cytostatic and cytotoxic activities, and is a competitive inhibitor of guanylate cyclase activity. This crude preparation kills human leukemic lymphocytes in a dose-dependent manner while not affecting the viability of normal human lymphocytes at these same doses. In this report we describe the purification and characterization of one of these cytostatic factors which also exhibits anti-viral activity. The partially purified factor was both cytostatic to BHK-21 cells and inhibitory to VSV plaque formation in a dose-dependent manner. This preparation was inhibitory to both viral and host cell RNA and protein synthesis as early as 30 min after addition to these samples. As determined by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), this purified factor is a single component with a molecular weight corresponding to 40,000 daltons. The factor is sensitive to boiling and to pre-treatments with trypsin, but not ribonuclease (RNAse), or deoxyribonuclease (DNAse). As determined by radioactive precursor uptake and incorporation studies, the purified factor inhibits both RNA and protein synthesis in intact tissue culture cells and inhibits protein synthesis in a cell-free wheat germ system. DNA synthesis was slightly stimulated. The purified factor is cytostatic for both BHK-21 and for the IM9 leukemic cell lines for at least 120 h. The cytostatic component had no effect on cellular cyclic GMP metabolism.


Subject(s)
Antiviral Agents/isolation & purification , Cell Division/drug effects , Plant Extracts/analysis , 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Antineoplastic Agents, Phytogenic/isolation & purification , Cell Line , DNA/biosynthesis , Guanylate Cyclase/antagonists & inhibitors , Humans , Lymphocytes/metabolism , Molecular Weight , Protein Biosynthesis , Viral Plaque Assay
5.
Prep Biochem ; 12(4): 355-75, 1982.
Article in English | MEDLINE | ID: mdl-6185939

ABSTRACT

In this report we describe the purification and characterization of a cytostatic factor from the bitter melon (Momordica charantia). As determined by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), this purified factor is a single component with an apparent molecular weight of 11,000. The factor is not sensitive to boiling or to pretreatments with trypsin, ribonuclease (RNAse), or deoxyribonuclease (DNAse). As determined by radioactive precursor uptake studies, the purified factor preferentially inhibits RNA synthesis in intact tissue culture cells. Some inhibition of protein synthesis and DNA synthesis also occurs. The factor is preferentially cytostatic for IM9 human leukemic lymphocytes when compared to normal human peripheral blood lymphocytes.


Subject(s)
Antibiotics, Antineoplastic/isolation & purification , Animals , Antibiotics, Antineoplastic/pharmacology , Cells, Cultured , DNA/biosynthesis , Dose-Response Relationship, Drug , Guanylate Cyclase/antagonists & inhibitors , Humans , Leukemia, Experimental/drug therapy , Leukemia, Experimental/enzymology , Lymphocytes/drug effects , Protein Biosynthesis , RNA/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...